Protein design specialist Nabla Bio has announced strategic collaborations with pharmaceutical giants AstraZeneca (AZ; NASDAQ: AZN), Bristol Myers Squibb (BMS; NYSE: BMY), and Takeda (NYSE: TAK). These partnerships underscore the biotech company’s commitment to leveraging its integrated AI and wet-lab technologies for the design of conformation- and target-selective antibody candidates. The focus is on developing therapies that target hard-to-drug membrane proteins, such as G protein-coupled receptors (GPCRs), ion channels, and transporters. The deals are valued at over USD 550 million in upfront and milestone payments, with the potential for additional sales royalties.
This announcement follows the successful closure of a USD 26 million Series A financing round for Nabla Bio, further bolstering the company’s resources to advance its innovative protein design capabilities.- Flcube.com
